The company, also known as DRW, shared early data on its forthcoming multiplex qPCR-based platform and infectious disease ...

The tool analyzes results from standard tests of organ function, tumor burden, and inflammation to predict whether lymphoma patients will respond to treatment.

A revolution in oncology could help the 18 million cancer survivors in the U.S. and bolster Guardant Health, Natera and Exact Sciences.